Patient Journey Agent

The supplied documents report treatment interruption and discontinuation drivers primarily for the bispecific T-cell engager blinatumomab (BLINCYTO). The label states that "Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO" and directs clinicians to "Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended," while "Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS)" also require clinicians to "Interrupt or discontinue BLINCYTO as recommended." The label additionally describes interruption-related administration patterns that could be inferable in claims, including "re-initiations (e.g., if treatment is interrupted for 4 or more hours)," hospitalization recommendations at cycle starts, and fixed treatment-free intervals consisting of "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval." The NCI PDQ document describes major ALL therapy classes used in induction, including "combination chemotherapy with prednisone, vincristine, and an anthracycline," with optional additions such as "asparaginase or cyclophosphamide," and notes regimen modification through "omission of L-asparaginase" and rapid relapse after imatinib-containing therapy, but it does not provide explicit claims-based discontinuation definitions, dose-reduction algorithms, or switching rules across ALL therapies. The supplied document addresses an anthracycline therapy class used in Acute Lymphoblastic Leukemia and reports discontinuation and dose-modification drivers centered on cardiomyopathy, hepatic impairment, infusion complications, and severe myelosuppression. Reported discontinuation drivers include: “Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy” and “Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection; discontinue Doxorubicin Hydrochloride Injection.” Dose reduction patterns are described for hepatic impairment, including “1.2–3 mg/dL 50%” and “3.1–5 mg/dL 75%,” and interruption/administration modification signals include “Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur” and “Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation.” The document also reports severe toxicity events that could be inferable in administrative claims data, including “serious infection, septic shock, requirement for transfusions, hospitalization, and death,” cardiomyopathy monitoring, and hospitalization-related complications, but it does not provide explicit claims-based line-of-therapy discontinuation algorithms, switching definitions, or coverage of other major ALL therapy classes. The supplied documents report toxicity-driven dose reduction and interruption signals for several ALL therapy classes, but they do not provide a comprehensive cross-class analysis of discontinuation, switching, or claims-based line-of-therapy algorithms through 2026-09-21. For vincristine-based therapy, co-administration with azoles was associated with increased neurotoxicity, CNS toxicity, intensive care use, and dose reduction; the text states that "Because of severe toxicities, vincristine treatment was significantly reduced (50% of normal dose) in several patients." For inotuzumab ozogamicin (BESPONSA), the label reports hepatotoxicity/VOD and liver test elevations as drivers of "dosing interruption, dose reduction, or permanent discontinuation," and notes that treatment cycles "may be extended up to 28 days" to allow recovery from toxicity. The documents do not define claims-based discontinuation rules, switching algorithms, or specific administrative claims indicators for line-of-therapy construction, although observable claims proxies inferable from the text could include ICU treatment, infusion timing extensions, and reduced administered dose intensity. The document describes major ALL therapy classes and some treatment-modification contexts, but it does not report administrative-claims algorithms for discontinuation, interruption, switching, or line-of-therapy construction. It states that ALL treatment commonly includes "Long-term chemotherapy (chemo)" and that "Other types of drugs, such as targeted drugs or immunotherapy, are sometimes part of treatment as well," with stem cell transplant as another option. Dose modification is mentioned for older or medically frail patients, where they "might not be able to tolerate an intensive induction regimen" and "reduced doses of many of these same drugs might be used." Toxicity- or tolerability-related treatment adjustment is indirectly referenced through statements that induction therapy is intensive, may require hospitalization, and that "serious infections or other complications can occur," but the document does not define discontinuation, interruption, switching rules, or claims-observable indicators through 2026-09-21. The supplied document only reports treatment modification and interruption drivers for doxorubicin-containing chemotherapy used in conditions including acute lymphoblastic leukemia, and it does not cover all major ALL therapy classes or comprehensive claims-based line-of-therapy algorithms through 2026-09-21. Reported discontinuation/interruption or dose-modification drivers include cardiotoxicity risk management, neutropenic fever/infection, delayed blood count recovery, unresolved nonhematologic toxicities, hyperbilirubinemia, and infusion-related extravasation concerns. Observable or inferable administrative claims signals from these events may include delayed treatment cycles, reduced administered dose intensity, therapy restarts after gaps, and supportive care or complication coding associated with neutropenic fever/infection or toxicity management, but the document does not explicitly define claims-based discontinuation rules. The supplied documents report that maintenance therapy for ALL commonly involves oral 6-mercaptopurine (6-MP) and methotrexate (MTX), and that these agents are associated with tolerability-driven dose modifications and adverse events. One study specifically aimed "to describe real-world dose adjustments of MTX and 6-MP during the maintenance therapy in young adults" and noted that these oral therapies "frequently cause adverse events." The documents do not provide comprehensive information on treatment discontinuation drivers, interruption patterns, therapy switching signals across all major ALL therapy classes, or validated administrative-claims definitions for discontinuation and line-of-therapy construction through 2026-09-21.

The documents identify several major ALL therapy classes and associated clinically significant adverse events. Conventional induction chemotherapy regimens for adult ALL include "prednisone, vincristine, and an anthracycline," with some regimens adding "asparaginase or cyclophosphamide." BLINCYTO (blinatumomab), a "bispecific CD19-directed CD3 T-cell engager," carries boxed warnings for "Cytokine Release Syndrome (CRS), which may be life-threatening or fatal" and "Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal," with recommendations to "Interrupt or discontinue BLINCYTO" and hospitalization recommendations during early treatment cycles. BESPONSA (inotuzumab ozogamicin), a "CD22-directed antibody and cytotoxic drug conjugate," is associated with "Hepatotoxicity, including fatal and life-threatening VOD," "higher post-HSCT non-relapse mortality," "Myelosuppression," "Infusion Related Reactions," and "QT Interval Prolongation"; the label states that liver test elevations "may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA" and that treatment should be "Permanently discontinue[d]" if VOD occurs. The supplied documents do not directly describe United States claims-data analyses through 2026-09-21 or explicitly define claims-identifiable adverse-event markers beyond hospitalization recommendations, treatment interruption/discontinuation instructions, dose modifications, and transplant-associated mortality risks. The supplied documents only address the anthracycline class represented by doxorubicin in ALL therapy, not all major ALL therapy classes. For doxorubicin, clinically significant adverse events include “Cardiomyopathy,” “Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS),” “Extravasation and Tissue Necrosis,” and “Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death.” The labeling also describes treatment modification and escalation patterns tied to adverse events, including that “Patients in the NSABP B-15 study could have dose modifications of AC to 75% of the starting doses for neutropenic fever/infection,” and that “the next cycle of treatment cycle was delayed until the absolute neutrophil count (ANC) was ≥1000 cells/mm3 and the platelet count was ≥100,000 cells/mm3 and nonhematologic toxicities had resolved.” Claims-identifiable markers explicitly described include hospitalization, transfusion requirement, septic shock, neutropenic fever/infection, skin grafting, and wide excision surgery associated with extravasation injuries. The document identifies major ALL therapy classes as "chemotherapy (chemo)," "targeted drugs," and "immunotherapy," noting that "For some people, a stem cell transplant might also be an option." During induction chemotherapy, treatment is described as intensive, and the document states that patients "may spend some or much of this time in the hospital, because serious infections or other complications can occur" and that "Sometimes, complications can be life-threatening." The text also describes treatment modification patterns based on tolerability, stating that older patients or those with serious health conditions "might not be able to tolerate an intensive induction regimen," so "reduced doses of many of these same drugs might be used" and "Other options could include treatment with the antibody-drug conjugate inotuzumab ozogamicin or a steroid drug such as dexamethasone or prednisone." The supplied document does not provide claims-data methodologies, adverse-event coding markers, discontinuation patterns, escalation patterns, or detailed toxicity profiles by therapy class through 2026-09-21. The supplied documents identify major ALL therapy categories and some general disease- and treatment-related clinical issues, but they do not provide a detailed mapping of clinically significant adverse events by therapy class, nor claims-based hospitalization, discontinuation, escalation, or treatment-modification patterns through 2026-09-21. The National Cancer Institute document states that “Previous chemotherapy and exposure to radiation may increase the risk of developing ALL,” and that “Leukemia may affect red blood cells, white blood cells, and platelets.” The Medscape reference lists major treatment components including “Induction Chemotherapy,” “Consolidation Therapy,” “Maintenance Therapy,” “CNS Prophylaxis,” and “Treatment of Ph Chromosome–Positive ALL,” but does not describe associated toxicities, hospitalization triggers, or claims-identifiable adverse-event markers. No supplied document reports claims-data analyses, hospitalization-associated adverse events, treatment discontinuation patterns, or escalation patterns tied to ALL therapy adverse events.

The supplied document indicates that the CIBMTR Disease Classification Form contains an Acute Lymphoblastic Leukemia section and captures disease-specific response information for hematopoietic cell transplantation reporting, including “disease type, subtype, transformations, cytogenetic and molecular markers, disease-specific laboratory results, staging, and disease status.” It also states that “Status at Transplantation” should be determined using CIBMTR manual guidelines because “there are many interpretations of disease response criteria,” and that “a majority of the disease response criteria are established by an international working group.” The document further specifies that diagnosis dates may derive from “bone marrow or tissue biopsy” or “pathological or laboratory assessment.” However, the document does not provide explicit Acute Lymphoblastic Leukemia response milestone definitions, measurable residual disease (MRD) criteria, MRD laboratory testing methods, monitoring schedules, or any discussion of what is directly observable, partially inferable, or absent in United States administrative claims data through 2026-09-21. The documents describe treatment-response evaluation in adult acute lymphoblastic leukemia (ALL) primarily through remission and survival outcomes after induction and postremission therapy. Reported response milestones include “complete response rates that range from 60% to 90%” and “436 achieved complete remission (78% +/- 2% for DNR v 74% +/- 3% for ZRB; P = .3),” as well as monitoring outcomes such as “disease relapse at a median of 58 days after the start of therapy,” “median duration of 2.2 months,” and “3-year disease-free survival.” Laboratory and pathology assessment evidence includes the existence of a “Bone marrow Pathology biopsy report” defined by LOINC code 33721-2. However, the supplied documents do not describe measurable residual disease (MRD) criteria, MRD laboratory methods, flow cytometry, molecular assays, PCR, next-generation sequencing, or any explicit administrative claims observability framework; therefore, direct versus inferable claims-data observability for these components cannot be determined from the documents. The document describes treatment response assessment criteria for relapsed or refractory CD22-positive B-cell precursor ALL using complete remission (CR), complete remission with incomplete hematologic recovery (CRi), bone marrow blast percentage, peripheral blood leukemic blasts, peripheral blood count recovery, and extramedullary disease resolution. It also references measurable residual disease (MRD) negativity as a treatment milestone relevant to hematopoietic stem cell transplant (HSCT) planning, but it does not describe MRD laboratory testing methods or monitoring procedures. The document includes laboratory and clinical monitoring elements such as bone marrow assessment, absolute neutrophil count (ANC), platelet count, bilirubin, AST/ALT, and peripheral blast count thresholds. The supplied source does not address administrative claims data observability, so no direct evidence is available regarding which response or MRD components are directly observable, partially inferable, or absent in claims data through 2026-09-21. The supplied documents provide only limited information relevant to treatment response evaluation in Acute Lymphoblastic Leukemia. One document identifies a bone marrow biopsy-related assessment element through the LOINC entry "Guidance for biopsy of Bone marrow," indicating that bone marrow biopsy procedures are represented in clinical terminology systems. Another document references the topic "Novel Therapies for Childhood Acute Lymphoblastic Leukemia" but does not provide details on response assessment criteria, measurable residual disease testing methods, monitoring procedures, response milestone definitions, or administrative claims observability limitations. The documents describe treatment response assessment in acute lymphoblastic leukemia (ALL) primarily through measurable residual disease (MRD) testing and risk stratification. MRD positivity is described as “commonly defined as at least 1 leukemia cell in 10,000 normal cells (expressed as 10-4)” and FDA-approved therapeutic decision making included “first or second complete remission with MRD greater than or equal to 0.1%.” Reported MRD laboratory methods include flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS), with monitoring performed on bone marrow aspirates and in some settings peripheral blood; flow cytometry requires “the first pull of bone marrow aspiration,” PCR is used commonly for “BCR/ABL gene rearrangements,” and NGS can monitor “immunoglobulin heavy chain receptor rearrangements or T-cell receptors.” The supplied documents do not directly address administrative claims data observability, but they describe clinical and laboratory components that are procedure- and result-based rather than billing-based, so direct claims observability of MRD status, assay sensitivity thresholds, immunophenotype findings, and remission definitions is not explicitly documented in the sources.

The supplied document positions BLINCYTO within several Acute Lymphoblastic Leukemia (ALL) treatment phases, including measurable residual disease treatment, relapsed/refractory therapy, and consolidation therapy. The document states that BLINCYTO is indicated for “CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%,” for “Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL),” and for “CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.” The document also describes induction, consolidation, and “continued therapy” cycles for relapsed/refractory disease. However, the supplied material does not describe the positioning of allogeneic hematopoietic stem cell transplant or CAR-T therapy within the ALL treatment journey, does not define terminal pathway states or post-treatment outcomes after those therapies, and does not provide claims-based procedure identification methods or coding approaches through 2026-09-21. The supplied document positions hematopoietic stem cell transplant (HSCT) as a downstream treatment pathway for patients with relapsed or refractory CD22-positive B-cell precursor ALL who respond to therapy with inotuzumab ozogamicin. The label states, “For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles,” with a possible third cycle if remission and MRD negativity are not achieved, indicating use as a bridge-to-transplant or consolidation approach before HSCT. The document also describes post-transplant outcome states and risks, including “Hepatotoxicity, including fatal and life-threatening VOD” and “higher post-HSCT non-relapse mortality rate.” The supplied material does not address CAR-T therapy positioning, salvage versus terminal pathway frameworks across all ALL patients in the United States, or claims-based procedure identification methods through 2026-09-21. The documents position allogeneic bone marrow transplant within the treatment journey for adult ALL as a consideration after induction or other chemotherapy responses because “remissions are generally short with conventional ALL chemotherapy clinical trials.” One document identifies tisagenlecleucel specifically as “a CAR-T cell therapy” used “for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States,” which places CAR-T therapy in the relapsed/refractory setting. The supplied documents do not describe transplant or CAR-T as consolidation, salvage, or terminal pathway states in broader U.S. ALL populations, do not describe post-treatment outcome states or bridge pathways, and do not provide claims-based procedure identification methods or coding approaches through 2026-09-21. The documents position CAR-T therapy for ALL primarily in the relapsed or refractory setting and describe bridging chemotherapy before infusion, while also discussing survivorship, toxicities, infections, and death after therapy as outcome states. One document states that “Three CAR T-cell products have been approved by the FDA to treat patients with relapsed or refractory B-cell ALL,” and another states that “While the CAR T cells are being manufactured, patients may receive additional chemotherapy to prevent their disease from progressing.” The supplied documents also describe post-treatment states including “short- and long-term side effects and toxicities,” “Infections,” survivorship, and “why some patients die from a CAR T-related toxicity.” The supplied documents do not provide a positioning for allogeneic hematopoietic stem cell transplant as consolidation, salvage, or terminal therapy, and they do not provide claims-based procedure identification methods or coding algorithms through 2026-09-21.

The document states that for adult ALL, “Treatment for ALL typically lasts for at least 2 years,” and that after treatment ends patients require “frequent follow-up exams and tests for at least several years,” which “will probably be every month or so at first, then less often as time passes.” Monitoring activities described include clinical examinations, symptom review, “blood tests, bone marrow exams, or other tests to look for treatment side effects or signs of leukemia,” as well as survivorship planning for “follow-up exams and tests,” “screening tests for other types of cancer,” and “tests to look for long-term health effects from your leukemia or its treatment.” The document also notes ongoing toxicity and side-effect monitoring, stating that “Almost any cancer treatment can have side effects,” and patients should report “any changes or problems.” The supplied document does not describe which monitoring activities can be captured or inferred from administrative claims data, and it does not provide detailed active-treatment monitoring cadence beyond treatment duration. The supplied document describes components of active treatment for adult Acute Lymphoblastic Leukemia (ALL) but does not provide recommended monitoring cadence during active treatment, remission surveillance, or post-treatment follow-up, and it does not discuss which monitoring activities can be captured in administrative claims data. The document states that induction therapy commonly uses multiagent chemotherapy regimens and mentions supportive care measures and hematopoietic growth factors during remission-induction therapy. No laboratory surveillance schedules, imaging frequency, toxicity-monitoring cadence, remission follow-up intervals, or claims-based monitoring definitions are provided in the supplied text. The supplied document does not provide recommendations for monitoring cadence during active treatment, remission surveillance, or post-treatment follow-up for Acute Lymphoblastic Leukemia in the United States. It also does not describe laboratory surveillance frequency, imaging schedules, toxicity monitoring cadence, or administrative claims methodologies. The only monitoring-related activity identifiable from the document is the existence of a LOINC-coded bone marrow pathology biopsy report: LOINC code 33721-2 is defined as "Bone marrow Pathology biopsy report." The supplied documents describe ALL management as prolonged and involving ongoing outpatient monitoring, but they do not provide specific recommended monitoring cadences for active treatment, remission surveillance, or post-treatment follow-up in the United States. One document states that "Over the course of 2 to 3 years, patients undergo treatment for induction, consolidation, maintenance, and possibly hematopoietic cell transplantation" and that outpatient management includes "adherence to medications, ambulatory treatment, and monitoring." The documents also describe toxicity and adverse-event monitoring during outpatient therapies, including that "nurses can provide close monitoring and rapid recognition of adverse events" for CAR-T therapy and that blinatumomab may continue as "home infusion therapy." These activities could potentially correspond to administrative claims-captured events such as outpatient visits, ambulatory treatments, home infusion services, medication-related encounters, and hospitalization periods, but the documents do not explicitly define claims-based capture methods, laboratory surveillance schedules, imaging schedules, or remission follow-up intervals.